<DOC>
	<DOCNO>NCT02773368</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare glycaemic control safety insulin degludec/liraglutide ( IDegLira ) versus insulin glargine ( IGlar ) add-on therapy SGLT2i ( sodium-glucose cotransporter 2 inhibitor ) subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Clinical Trial Comparing Glycaemic Control Safety Insulin Degludec/Liraglutide ( IDegLira ) Versus Insulin Glargine ( IGlar ) add-on Therapy SGLT2i Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female , age least 18 year time signing informed consent Subjects diagnose ( clinically ) type 2 diabetes mellitus HbA1c 7.011.0 % [ 5397 mmol/mol ] ( inclusive ) central laboratory analysis Body mass index ( BMI ) equal 20 kg/m^2 40 kg/m^2 Insulin naïve subject ; however short term insulin treatment maximum 14 day prior day screen allow , well prior insulin treatment gestational diabetes A stable daily dose least 90 day prior day screen SGLT2i monotherapy combination metformin ± DPP4i ± pioglitazone . Use pioglitazone allow subject treat dapagliflozin Receipt investigational medicinal product within 90 day prior screen Use OADs ( SGLT2i monotherapy combination metformin DPP4i pioglitazone describe inclusion criterion ) within 90 day prior day screen Use glucagonlike peptide1 ( GLP1 ) receptor agonist ( e.g. , exenatide liraglutide ) within 90 day prior day screen Acute decompensation glycaemic control require immediate intensification treatment prevent severe metabolic dysregulation ( e.g. , diabetes ketoacidosis ) previous 90 day prior day screen Subjects presently classify NYHA ( New York Heart Association ) Class III IV1 Renal impairment estimate Glomerular Filtration Rate 60 mL/min/1.73 m2 per CKDEPI ( Chronic Kidney Disease Epidemiology Collaboration ) Impaired liver function , define ALT ( alanine aminotransferase ) equal 2.5 time upper normal limit screen Known suspect hypersensitivity trial product ( ) relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>